ZHUZINC ZINC SULFATE HEPTAHYDRATE FOR SHEEP AND GOATS Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zhuzinc zinc sulfate heptahydrate for sheep and goats

redox limited - zinc sulfate heptahydrate - topical solution/suspension - zinc sulfate heptahydrate mineral-zinc active 980.0 g/kg - dermatological preps. - goat | sheep | billy | buck | capra hircus | doe | ewe | hogget | kid | lamb | ovine | ram | weaner | wether - bacterial prevention, cleansing or disin | mycotic dermatitis | disinfecting

SPIRONOLACTONE TEVA   100 MG Israel - English - Ministry of Health

spironolactone teva 100 mg

teva israel ltd - spironolactone - tablets - spironolactone 100 mg - spironolactone - spironolactone - edematous conditions: congestive heart failure; cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.

INCA 3 IRON-IRON COPPER COBALT & MANGANESE ORAL SUPPLEMENT FOR HORSES AND GREYHOUNDS Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

inca 3 iron-iron copper cobalt & manganese oral supplement for horses and greyhounds

inca (flight) co pty ltd - cobalt as cobaltous sulfate heptahydrate; copper present as copper sulfate pentahydrate; iron as ferric ammonium citrate, ferrous gluconate, ferr; manganese as manganese sulfate monohydrate - oral solution/suspension - cobalt as cobaltous sulfate heptahydrate mineral-cobalt active 0.2 mg/l; copper present as copper sulfate pentahydrate mineral-copper active 14.7 mg/l; iron as ferric ammonium citrate, ferrous gluconate, ferr mineral-iron active 16.0 g/l; manganese as manganese sulfate monohydrate mineral-manganese active 14.9 mg/l - nutrition & metabolism - dog - greyhound | horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | - iron supplement

BUSPIRONE HYDROCHLORIDE tablet United States - English - NLM (National Library of Medicine)

buspirone hydrochloride tablet

redpharm drug, inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 5 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual du

SPIRONOLACTONE tablet United States - English - NLM (National Library of Medicine)

spironolactone tablet

contract pharmacy services-pa - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: - establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. - short-term preoperative treatment of patients with primary hyperaldosteronism. short-term preoperative treatment of patients with primary hyperaldosteronism. - long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. - long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edema

SPIRONOLACTONE tablet United States - English - NLM (National Library of Medicine)

spironolactone tablet

blenheim pharmacal, inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: - establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. - short-term preoperative treatment of patients with primary hyperaldosteronism. short-term preoperative treatment of patients with primary hyperaldosteronism. - long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. - long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edema

SPIRONOLACTONE tablet United States - English - NLM (National Library of Medicine)

spironolactone tablet

state of florida doh central pharmacy - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: - establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. - short-term preoperative treatment of patients with primary hyperaldosteronism. short-term preoperative treatment of patients with primary hyperaldosteronism. - long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. - long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edema

SPIRONOLACTONE- spironolactone tablet, film coated United States - English - NLM (National Library of Medicine)

spironolactone- spironolactone tablet, film coated

major pharmaceuticals - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone tablets, usp are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: spironolactone levels may be exceptiona

SPIRONOLACTONE- spironolactone tablet United States - English - NLM (National Library of Medicine)

spironolactone- spironolactone tablet

preferred pharmaceuticals, inc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone tablets, usp are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: spironolactone levels may be exceptiona

BUSPIRONE HYDROCHLORIDE tablet United States - English - NLM (National Library of Medicine)

buspirone hydrochloride tablet

preferred pharmaceuticals inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 15 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual d